Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Oktober 2020

Planlagt Fastgjort Låst Flyttet Genmab
767 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #266

    I think 10:50 points to amivantamab filing in Q4?

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #267

      Beyond that i can only find JNJ-7957 (BCMA/CD3), JNJ-7564 (GPRC5D/CD3) for planned filing 2020-2023

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #268

        10:50 E L - ohh yes sorry !

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #269

          Thx E L

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #270

            I didn't realize we were that close to an amivantamab filing.

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #271

              Its going to be fun to see milestones for filing and approval to get a feeling about how backloaded these Duobody deals are

              1 Reply Last reply
              0
              • bongobobB Offline
                bongobobB Offline
                bongobob
                wrote on sidst redigeret af
                #272

                Meget informativt om Amivantamab. 6-12 md approval...moving to 1.line... Beklager hvis den har været linket. https://www.docwirenews.com/hematology-oncology/amivantamab-plus-lazertinib-combo-show-promising-results-at-esmo-2020/

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #273

                  SITC ID: 561
                  DuoBody®-PD-L1×4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13906&CONF=SITC20&ssoOverride=OFF&CKEY=

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    GeorgeBest
                    wrote on sidst redigeret af
                    #274

                    Thanks E L and bongobob

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #275

                      SITC ID: 412
                      First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumors https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13347&CONF=SITC20&ssoOverride=OFF&CKEY=

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        GeorgeBest
                        wrote on sidst redigeret af
                        #276

                        12:40 I like the phrase “superior”

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #277

                          Conclusions DuoBody-PD-L1×4-1BB demonstrated biologic activity and a manageable safety profile. Encouraging early clinical activity across different dose levels was observed in a heavily pretreated population with advanced solid tumors, including those resistant to prior immunotherapy or typically less sensitive to ICIs. Expansion cohorts of patients for whom DuoBody-PD-L1×4-1BB treatment could be relevant and biologically sound have started enrollment. Updated data will be presented.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #278

                            Disease control, including stable disease at first assessment and partial responses in triple-negative breast cancer, ovarian cancer, and immune checkpoint inhibitor (ICI)–pretreated NSCLC, occurred in 40/61 patients (65.6%).

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #279

                              SITC ID: 704
                              Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13592&CONF=SITC20&ssoOverride=OFF&CKEY=

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #280

                                Opdaterede salgstal på Darzalex. https://www.proinvestor.com/boards/87573#87574

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #281

                                  SITC ID: 617
                                  Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13984&CONF=SITC20&ssoOverride=OFF&CKEY=

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #282

                                    SITC ID: 621
                                    A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13536&CONF=SITC20&ssoOverride=OFF&CKEY= (camidanlumab tesirine (ADCT-301))

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      Plimsoller
                                      wrote on sidst redigeret af
                                      #283

                                      Tak Helge. Projekteret i den øveste del af intervallet. Hvis det ender sådan, så kan vi ikke klage 🙂

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #284

                                        Tak bongo. Så amivantamab 100% RR i første linje (få pts ganske vist) og godkendelse om et par år.

                                        1 Reply Last reply
                                        0
                                        • bongobobB Offline
                                          bongobobB Offline
                                          bongobob
                                          wrote on sidst redigeret af
                                          #285

                                          Fantastiske nyheder både Amivantamab og PD-L1x4-1BB. Duobody validated

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger